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Introduction
The current study explores quitting behaviours and use 
of cessation assistance among adult tobacco users with 
probable anxiety or depression (PAD) and in six European 
(EU) Member States (MS). 
Methods
The EUREST-PLUS ITC Wave 1 Europe Survey was 
conducted with a nationally representative cross-
sectional sample of 6,011 adult cigarette smokers from 
six European Union (EU) Member States (MS) (Germany, 
Greece, Hungary, Poland, Romania, Spain) in 2016. 
Results
Our study found that one in five smokers sampled from six 
EU MS had a diagnosis, treatment or positive screen for 
anxiety or depression, with rates of PAD varying between 
EU MS. Results of the multivariable logistic regression 
analysis showed that respondents with PAD were more 
likely to have made a quit attempt in the last 12 months 
(AOR 1.75; 95%CI 1.45-2.11), compared to respondents 
without PAD. Among those respondents with PAD who 
used support the most frequently reported quit method 
was prescription-based quit smoking pharmacotherapy 
(15.4%) followed by e-cigarettes (13.7%) and NRT (11.3%). 
Person-to-person behavioral support (i.e. local quit 
services, face-to-face advice from a doctor or other health 
care professional, telephone or quitline services) was 
reported significantly more frequently among respondents 
with PAD compared to those without PAD. 
Conclusions
Given both pharmacological and non-pharmacological quit 
smoking aids have been shown to be safe, acceptable and 
effective for people with and without mental illness it is 
important that their use be promoted among smokers with 
anxiety and depression alongside behavioral counseling. 
Our findings support the need for interventions targeting 
health care professionals in providing smoking cessation 
assistance among this population of smokers.
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